Ciprofloxacin HCl Pharma Grade API for Tablet / Capsule / Granule / Injection, Oral & Injectable is the monohydrochloride monohydrate salt of 1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid, a fluoroquinolone carboxylic acid derivative with activity against bacterial DNA gyrase, also termed topoisomerase II, and topoisomerase IV. The compound is assigned CAS RN 86393-32-0 and has the molecular formula C₁₇H₁₈FN₃O₃·HCl·H₂O, corresponding to a relative molecular mass of 385.82 g/mol. The hydrochloride salt is supplied as a white to pale yellow crystalline powder against current compendial monographs for ciprofloxacin hydrochloride in USP, EP, BP, IP, and JP. Product grades are separated into oral-grade material for tablet, capsule, and granule processes and injectable-grade material for aqueous parenteral manufacturing; no single acceptance criterion set can be applied across both routes without route-specific qualification.

The salt form is selected because ciprofloxacin base exhibits poor aqueous solubility. Conversion to the hydrochloride monohydrate provides a formulation-usable material that can be wet granulated, dry granulated, or dry blended, and that can be dissolved in acidified aqueous vehicles for injectable processing. The stoichiometric conversion factor from ciprofloxacin base to the hydrochloride monohydrate is approximately 1.164. The API is not a prodrug; after administration, the salt dissociates and the zwitterionic ciprofloxacin moiety distributes into tissues. The product differs from ciprofloxacin base, which is rarely used without salt conversion or substantial particle size reduction, and from ciprofloxacin lactate, which is frequently selected for ready-to-use intravenous solutions. Differences are defined by salt stoichiometry, aqueous solubility, solution pH, route-specific impurity controls, and compendial monograph status.

What distinguishes the hydrochloride salt from the free base in solid oral dosage processing?

Solid oral development with ciprofloxacin HCl is governed by pH-dependent solubility rather than by the intrinsic dissolution rate of the free base. Reported pKa values for ciprofloxacin are approximately 6.1 and 8.6 in dilute aqueous solution, placing the zwitterionic form across the gastrointestinal pH range. The hydrochloride salt increases dissolution in acidic media, but solubility can decline as pH approaches neutral. Tablet and capsule formulations are therefore developed with dissolution testing under compendial conditions referenced to USP <711>, and the finished-product dissolution acceptance criteria are tied to the specific formulation rather than to the API alone. The free base is practically insoluble in water and would require more aggressive particle size reduction, surface-active wetting, or alternative delivery; the hydrochloride salt avoids this limitation while introducing sensitivity to alkaline excipients.

Magnesium-, calcium-, and aluminium-containing excipients must be assessed for compatibility because ciprofloxacin can form complexes with polyvalent cations. If such interactions occur in the dosage form, dissolution and bioavailability may be affected, and the clinical interaction with antacid products is documented in finished-product labeling. For this reason, matrix systems and buffer excipients containing calcium hydrogen phosphate or magnesium aluminium silicate require dedicated stability and dissolution studies before inclusion.

When ciprofloxacin HCl is specified for injectable formulations

Injectable-grade ciprofloxacin HCl imposes route-specific controls that are not required for oral-grade material. Bacterial endotoxin testing is conducted according to USP <85> or EP 2.6.14, and bioburden testing according to USP <61> and USP <62>. Particulate matter in the final solution is addressed by USP <788>. The hydrochloride salt is dissolved in Water for Injection with acidification; finished-product labeling for ciprofloxacin intravenous solutions commonly lists pH 3.5–4.6 to balance solubility and chemical stability. Above this acidic window, precipitation can occur; below it, local irritation and acid-catalyzed degradation must be controlled. pH specification and buffer type are therefore critical formulation parameters.

For sterilization, aseptic filtration is commonly used for parenteral fluoroquinolones, but terminal sterilization at 121 °C may be considered only when thermal stability data demonstrate no increase in specified degradation products above the registered limit. Solutions should be protected from light and stored in containers that limit oxygen permeation. Contact with alkaline buffers, phosphate-precipitating systems, and polyvalent cations should be avoided during compounding and fill-finish operations because ciprofloxacin can precipitate or form complexes at neutral to alkaline pH.

Solid oral dosage-form development with ciprofloxacin HCl operates in a high-drug-load range. For label strengths of 250 mg, 500 mg, and 750 mg base equivalent, the hydrochloride monohydrate mass can exceed 50% w/w of the tablet core. Blend uniformity therefore depends on API particle size distribution, bulk density, and surface properties rather than on gravimetric addition alone. Particle size distribution is measured by laser diffraction per USP <429> or ISO 13320-1:2020, and content uniformity of the finished unit is assessed per USP <905>. If the API lot contains agglomerates from storage, milling is introduced; however, excessive energy input increases electrostatic adhesion and can create fines that segregate in direct compression. Roller compaction and high-shear wet granulation are both used to reduce segregation and improve flow. For granules for oral suspension, particle size and wetting are additional controls because agglomerated API can settle rapidly and produce non-uniform dosing.

Pharmacopoeial Specification Matrix for Oral and Injectable Grades

The following parameters are applied to ciprofloxacin HCl API according to route and registered formulation. Not every parameter is required for every product; injectable grades require additional endotoxin and particulate matter controls.

Elemental impurities are controlled according to ICH Q3D risk assessment using USP <232>/<233> or equivalent EP procedures. Residual solvents are specified only for solvents used in the final synthetic steps and purification steps. Injectable-grade release additionally requires depyrogenation and compatibility with sterilizing-grade filtration.

Wet granulation and roll compaction boundaries are set by dissolution rather than particle size alone

During high-shear wet granulation, ciprofloxacin HCl can become over-wetted within a narrow liquid addition range. The end point is better controlled by impeller torque and product temperature than by a fixed time. Over-granulation reduces intragranular porosity and slows tablet dissolution even when particle size distribution appears acceptable. Consequently, dissolution testing per USP <711> is the primary quality target, with disintegration per USP <701> used as a routine control. For aqueous film-coated tablets, pan moisture and spray rate are adjusted so that the core does not pick up moisture above the validated limit during coating.

In roll compaction, ribbon density and granule porosity are controlled by roll gap, roll speed, and hydraulic pressure. High ribbon density improves granule strength but may reduce dissolution if the compacted material has low intragranular porosity. The accepted operating window is established by linking roll parameters to dissolution response rather than by mechanical strength alone. Water content is measured by Karl Fischer titration per USP <921> and is controlled because monohydrate stoichiometry affects mass balance and potency labeling. Near-infrared moisture monitoring is often configured on the granulator or blender to detect water excursion before it reaches the tablet press.

Bulk oral-grade ciprofloxacin HCl is typically packed in double polyethylene liners within fiber or HDPE drums. Injectable-grade material is packed with desiccant and, where required, under nitrogen to limit oxygen and moisture ingress. Storage is controlled at room temperature and protected from light. Moisture uptake above the monohydrate water content can affect flow, assay on dried basis, and granulation endpoint. If oral-grade material is considered for injectable development after initial release, additional bacterial endotoxin, bioburden, particulate matter, and sterilizing-filter compatibility data are required because oral and injectable acceptance criteria are not interchangeable. Formulation studies should avoid unqualified contact with alkaline excipients, multivalent cation-containing additives, and oxidative packaging environments without supporting compatibility data.